Structure-activity studies of a novel series of isoxazole-3-carboxamide derivatives as TRPV1 antagonists

Ronald Palin, Lynn Abernethy, Nasrin Ansari, Kenneth Cameron, Tom Clarkson, Maureen Dempster, David Dunn, Anna Marie Easson, Darren Edwards, John MacLean, Katy Everett, Helen Feilden, Koc Kan Ho, Steve Kultgen, Peter Littlewood, Duncan McArthur, Deborah McGregor, Hazel McLuskey, Irina Neagu, Stuart NealeLesley Anne Nisbet, Michael Ohlmeyer, Quynhchi Pham, Paul Ratcliffe, Yajing Rong, Andrew Roughton, Melanie Sammons, Robert Swanson, Heather Tracey, Glenn Walker

Research output: Contribution to journalArticlepeer-review

23 Scopus citations

Abstract

Optimisation of a screening hit incorporating both TRPV1 activity and solubility was conducted. Substitution of the isoxazole-3-carboxamide with the bespoke 1S, 3R-3-aminocyclohexanol motif afforded the requisite balance of potency and solubility. Compounds 32 and 40 were found to have antihyperalgesic effects in the rat CFA Hg assay and induce a mechanism based hyperthermia.

Original languageEnglish
Pages (from-to)892-898
Number of pages7
JournalBioorganic and Medicinal Chemistry Letters
Volume21
Issue number3
DOIs
StatePublished - 1 Feb 2011
Externally publishedYes

Keywords

  • Antihyperalgesia
  • Hyperthermia
  • Isoxazoles
  • TRPV1 antagonist

Fingerprint

Dive into the research topics of 'Structure-activity studies of a novel series of isoxazole-3-carboxamide derivatives as TRPV1 antagonists'. Together they form a unique fingerprint.

Cite this